推荐产品
等級
pharmaceutical primary standard
API 家族
ursodeoxycholic acid
製造商／商標名
EDQM
mp
203-204 °C (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChI
1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
InChI 密鑰
RUDATBOHQWOJDD-UZVSRGJWSA-N
基因資訊
human ... NR1H4(9971)
正在寻找类似产品? 访问 产品对比指南
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Marco Carbone et al.
Gastroenterology, 144(3), 560-569 (2012-12-19)
BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have been performed using small and selected populations. Study size has precluded investigation of important disease subgroups, such as men and young patients. We used a national patient cohort
John E Eaton et al.
Gastroenterology, 145(3), 521-536 (2013-07-06)
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
Marcelo G Roma et al.
Clinical science (London, England : 1979), 121(12), 523-544 (2011-08-23)
UDCA (ursodeoxycholic acid) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies. Its use has expanded to other kinds of hepatic diseases, and even to extrahepatic ones. Such versatility is the result of its multiple mechanisms
Yan Gong et al.
The American journal of gastroenterology, 102(8), 1799-1807 (2007-04-27)
Ursodeoxycholic acid (UDCA) is used for primary biliary cirrhosis (PBC), but the beneficial effects remain controversial. We performed an updated systematic review to evaluate the benefits and harms of UDCA in patients with PBC. We included randomized clinical trials evaluating
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门